Fate Therapeutics将在2026年美国基因与细胞治疗学会年会展示三项研究成果,重点推介针对癌症及自身免疫性疾病的现货型CAR-T细胞疗法管线

美股速递
May 04

Fate Therapeutics公司近日宣布,其研发团队将于2026年美国基因与细胞治疗学会(ASGCT)年会上进行三项重要研究成果展示。这些报告将集中呈现该公司在现货型CAR-T细胞疗法领域的最新突破,相关疗法主要针对癌症与自身免疫性疾病两大治疗方向。

此次学术会议将成为Fate Therapeutics展示其创新疗法管线的重要平台。通过三项专题报告,研发人员将详细阐述其在同种异体CAR-T细胞治疗技术方面的进展,包括治疗机制、临床前数据及未来临床应用前景。这些研究成果有望为癌症和自身免疫性疾病患者提供更具可及性的现成细胞治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10